4.60
+3.37%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gaush Meditech
Its shares trade on HKEX under the ticker 2407.HK. It has been listed since 12 December 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.38bn and net income of CN¥96.2m. At that date it held total assets of CN¥2.63bn and shareholders' equity of CN¥1.69bn.
Gaush Meditech Ltd. is an investment holding company, which engages in the provision of ophthalmic medical devices. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-12-12. The firm operates in four segments. Proprietary Products segment develops and produces surgical equipment and related supporting software, intra optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables. Distribution segment sells brand ophthalmic medical devices and consumables. Technical Services segment provides warranty service, maintenance service and consumables related to after-sales service. Others segment is mainly engaged in equipment leasing business and intellectual property agency services. The firm's products are widely used in the examination, treatment and correction of ophthalmic subspecialty diseases such as fundus disease, cataract, glaucoma, refraction, optometry, ocular surface, and children's ophthalmology.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 12 Dec 2022
- Employees
- 821
- Website
- gaush.com ↗
Leadership
Pay as last reported
- Mr. Tieta GaoExecutive Chairman of the Board, since 2017CN¥1.2m
- Mr. Xinwei LiuChief Executive Officer, Executive Director, since 2019CN¥1.1m
- Ms. Wenqi LiChief Financial Officer, Executive Director, since 2018
- Mr. Xinli ZhaoChief Compliance Officer, Executive Director, since 2017CN¥1.0m
- Mr. Jianjun ZhangHonorary President, Executive Director, since 2017CN¥1.2m
- Ms. Shui Bing LeungJoint Company Secretary
- Mr. Bo ZhangJoint Company Secretary
- Dr. Wang GuoweiNon-Executive Director
- Mr. Fan Shing ChanNon-Executive Independent Director
- Mr. Xin FengNon-Executive Independent Director
- Mr. Li Shin WangNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Proprietary Products segment develops surgical equipment and intra optical lenses for ophthalmic diseases.
- Distribution segment sells brand ophthalmic medical devices and consumables across China.
- Technical Services segment provides warranty and maintenance services for ophthalmic equipment in Beijing.
Weaknesses
- Employees count of 821 is lower than industry average for Health Care sector.
- Listed date of 12 December 2022 is recent for a mature market.
- Business segments include equipment leasing which is less profitable than core medical devices.
Opportunities
- Growing demand for ophthalmic devices in China's aging population.
- Expansion into new ophthalmic disease segments like children's ophthalmology.
- Increased focus on eye health in China's healthcare reforms.
Threats
- Competition from established ophthalmic device manufacturers in China.
- Regulatory changes in China's Health Care sector could affect product approvals.
- Economic downturns may reduce hospital spending on medical equipment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.